AR047469A1 - Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas - Google Patents
Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidasInfo
- Publication number
- AR047469A1 AR047469A1 ARP050100283A ARP050100283A AR047469A1 AR 047469 A1 AR047469 A1 AR 047469A1 AR P050100283 A ARP050100283 A AR P050100283A AR P050100283 A ARP050100283 A AR P050100283A AR 047469 A1 AR047469 A1 AR 047469A1
- Authority
- AR
- Argentina
- Prior art keywords
- preservants
- cyclodextrines
- antimicrobial
- beta
- achieve
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54089704P | 2004-01-30 | 2004-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047469A1 true AR047469A1 (es) | 2006-01-18 |
Family
ID=34910697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100283A AR047469A1 (es) | 2004-01-30 | 2005-01-27 | Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas |
| ARP170102291A AR109357A2 (es) | 2004-01-30 | 2017-08-16 | Composición farmacéutica parenteral con tolerancia en el sitio de inyección |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102291A AR109357A2 (es) | 2004-01-30 | 2017-08-16 | Composición farmacéutica parenteral con tolerancia en el sitio de inyección |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8183230B2 (enExample) |
| EP (1) | EP1713504B1 (enExample) |
| JP (1) | JP5021318B2 (enExample) |
| KR (1) | KR100834232B1 (enExample) |
| CN (1) | CN101090735A (enExample) |
| AR (2) | AR047469A1 (enExample) |
| AU (1) | AU2005216709B2 (enExample) |
| BR (1) | BRPI0506496B8 (enExample) |
| CA (1) | CA2554346C (enExample) |
| CO (1) | CO5700794A2 (enExample) |
| CY (1) | CY1119188T1 (enExample) |
| DK (1) | DK1713504T3 (enExample) |
| ES (1) | ES2638113T3 (enExample) |
| HU (1) | HUE034099T2 (enExample) |
| IL (1) | IL176676A0 (enExample) |
| LT (1) | LT1713504T (enExample) |
| NO (1) | NO20063858L (enExample) |
| NZ (1) | NZ548236A (enExample) |
| PL (1) | PL1713504T3 (enExample) |
| PT (1) | PT1713504T (enExample) |
| RU (1) | RU2332997C2 (enExample) |
| SI (1) | SI1713504T1 (enExample) |
| TW (1) | TW200524632A (enExample) |
| WO (1) | WO2005082416A2 (enExample) |
| ZA (1) | ZA200605148B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| CA2852716C (en) * | 2011-11-29 | 2015-11-17 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| HRP20251029T1 (hr) | 2013-07-19 | 2025-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Konzervirani eterificirani derivati ciklodekstrina koji sadrže tekući vodeni farmaceutski pripravak |
| PL3106150T3 (pl) | 2013-12-04 | 2022-01-03 | Boehringer Ingelheim Vetmedica Gmbh | Ulepszone kompozycje farmaceutyczne pimobendanu |
| NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| EP3645120B1 (en) | 2017-06-30 | 2024-12-11 | Chase Therapeutics Corporation | Nk-1 antagonist compositions and methods for use in treating depression |
| CA3129648A1 (en) * | 2019-02-15 | 2020-08-20 | Saol International Limited | Injectable formulations comprising phenol and cyclodextrin and uses thereof________________________________ |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| CN112370451A (zh) * | 2020-12-08 | 2021-02-19 | 河北科技大学 | 一种枸橼酸马罗匹坦包合物、注射液及制备方法 |
| AT527172A1 (de) * | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5910510A (ja) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | 低刺激性チアムリン注射剤 |
| JPS59152320A (ja) * | 1983-02-17 | 1984-08-31 | Takeda Chem Ind Ltd | 水性製剤 |
| JPS6419737A (en) * | 1987-07-15 | 1989-01-23 | Hitachi Ltd | Multilayer interconnection tape carrier |
| JPH039848A (ja) * | 1989-06-06 | 1991-01-17 | Canon Inc | 液体噴射記録装置 |
| WO1992021677A1 (en) | 1991-05-31 | 1992-12-10 | Pfizer Inc. | bibNUCLIDINE DERIVATIVES |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| KR950704311A (ko) | 1992-11-12 | 1995-11-17 | 알렌 제이. 스피겔 | 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist) |
| US5393762A (en) | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| WO2000012137A1 (en) | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US6255320B1 (en) | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| AU5975700A (en) * | 1999-07-02 | 2001-01-22 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| KR20040029375A (ko) * | 2001-07-20 | 2004-04-06 | 화이자 프로덕츠 인코포레이티드 | 개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한nk-1 수용체 길항제의 용도 |
| WO2003072141A1 (en) | 2002-02-22 | 2003-09-04 | Pharmacia Corporation | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| DE10228049A1 (de) | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
| US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
| MXPA06008648A (es) | 2004-01-30 | 2006-09-04 | Pfizer Prod Inc | Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion. |
| WO2005082366A1 (en) | 2004-01-30 | 2005-09-09 | Pfizer Products Inc. | Nk-1 receptor antagonists anesthesia recovery |
| ES2296131T3 (es) | 2004-02-02 | 2008-04-16 | Pfizer Products Incorporated | Procedimiento para la preparacion de 1-(2s,3s)-2-bencidril-n-(5-terc-butil-2-metoxibencil)quinuclidin-3-amina. |
-
2005
- 2005-01-17 EP EP05702263.4A patent/EP1713504B1/en not_active Expired - Lifetime
- 2005-01-17 PL PL05702263T patent/PL1713504T3/pl unknown
- 2005-01-17 AU AU2005216709A patent/AU2005216709B2/en not_active Expired
- 2005-01-17 NZ NZ548236A patent/NZ548236A/en not_active IP Right Cessation
- 2005-01-17 SI SI200532166T patent/SI1713504T1/sl unknown
- 2005-01-17 DK DK05702263.4T patent/DK1713504T3/en active
- 2005-01-17 US US10/588,070 patent/US8183230B2/en active Active
- 2005-01-17 LT LTEP05702263.4T patent/LT1713504T/lt unknown
- 2005-01-17 RU RU2006127422/15A patent/RU2332997C2/ru not_active IP Right Cessation
- 2005-01-17 CA CA002554346A patent/CA2554346C/en not_active Expired - Lifetime
- 2005-01-17 BR BRPI0506496A patent/BRPI0506496B8/pt active IP Right Grant
- 2005-01-17 KR KR1020067015283A patent/KR100834232B1/ko not_active Expired - Lifetime
- 2005-01-17 PT PT57022634T patent/PT1713504T/pt unknown
- 2005-01-17 ES ES05702263.4T patent/ES2638113T3/es not_active Expired - Lifetime
- 2005-01-17 HU HUE05702263A patent/HUE034099T2/en unknown
- 2005-01-17 JP JP2006550330A patent/JP5021318B2/ja not_active Expired - Lifetime
- 2005-01-17 WO PCT/IB2005/000100 patent/WO2005082416A2/en not_active Ceased
- 2005-01-17 CN CNA2005800032849A patent/CN101090735A/zh active Pending
- 2005-01-27 AR ARP050100283A patent/AR047469A1/es not_active Application Discontinuation
- 2005-01-28 TW TW094102680A patent/TW200524632A/zh unknown
-
2006
- 2006-06-22 ZA ZA200605148A patent/ZA200605148B/en unknown
- 2006-07-03 IL IL176676A patent/IL176676A0/en unknown
- 2006-07-26 CO CO06073023A patent/CO5700794A2/es not_active Application Discontinuation
- 2006-08-29 NO NO20063858A patent/NO20063858L/no not_active Application Discontinuation
-
2017
- 2017-08-04 CY CY20171100843T patent/CY1119188T1/el unknown
- 2017-08-16 AR ARP170102291A patent/AR109357A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
| CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
| BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
| EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| ECSP109905A (es) | Moduladores de receptor 7 tipo toll | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
| AR109357A2 (es) | Composición farmacéutica parenteral con tolerancia en el sitio de inyección | |
| UA110013C2 (uk) | Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів | |
| CO5580767A2 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| AR059501A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| US20080255079A1 (en) | Therapeutic Use of Nefopam and Analogues Thereof | |
| AR058619A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
| UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas | |
| PA8579701A1 (es) | Profarmaco inhibidor de beta-lactamasa | |
| RU2332989C2 (ru) | Способ получения 1r,2s-метоксамина, его терапевтическое применение (варианты) и фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |